Frontiers in medicine · 2025
Platelet count and clinical outcomes in hospitalized patients with COVID-19 pneumonia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siniscalchi Carmine, Di Micco Pierpaolo, Guerra Angela, Simoni Riccardo, Magro Julia, Parise Alberto, Cerundolo Nicoletta, Imbalzano Egidio, Tana Claudio, Finardi Lorenzo, Meschi Tiziana
Аннотация
BACKGROUND: Thrombocytopenia has been associated with poor outcomes in various infectious diseases, including COVID-19. This study investigates the relationship between platelet (PLT) count at hospital admission and clinical characteristics, treatments, and outcomes in patients with COVID-19 pneumonia.
METHODS: We retrospectively analyzed 797 patients hospitalized for COVID-19 pneumonia, stratifying them into three groups by platelet count: <150,000/mm3 (22%), 150,000-400,000/mm3 (76%), and >400,000/mm3 (2.5%).
RESULTS: Patients with PLT < 150,000/mm3, more frequently male, and had a higher prevalence of cirrhosis and fibrosis. They presented less severe respiratory impairment and lower inflammatory markers. They also showed lower use of enoxaparin and a higher use of fondaparinux. Mortality was at the limits of significance in this group (37% vs. 28 and 20%, p = 0.056), and thrombocytopenia was independently associated with increased risk of in-hospital death (HR 1.483, 95% CI 1.023-2.150; p = 0.037).
CONCLUSION: Thrombocytopenia on admission independently predicts mortality in patients hospitalized with COVID-19 pneumonia.
METHODS: We retrospectively analyzed 797 patients hospitalized for COVID-19 pneumonia, stratifying them into three groups by platelet count: <150,000/mm3 (22%), 150,000-400,000/mm3 (76%), and >400,000/mm3 (2.5%).
RESULTS: Patients with PLT < 150,000/mm3, more frequently male, and had a higher prevalence of cirrhosis and fibrosis. They presented less severe respiratory impairment and lower inflammatory markers. They also showed lower use of enoxaparin and a higher use of fondaparinux. Mortality was at the limits of significance in this group (37% vs. 28 and 20%, p = 0.056), and thrombocytopenia was independently associated with increased risk of in-hospital death (HR 1.483, 95% CI 1.023-2.150; p = 0.037).
CONCLUSION: Thrombocytopenia on admission independently predicts mortality in patients hospitalized with COVID-19 pneumonia.